J&J Gains 1.7% as Caplyta Opens a Mania Expansion Path
Johnson & Johnson NYSE:JNJ, the healthcare and pharmaceutical company, reported positive Phase 3 results for Caplyta in adults with bipolar I mania. Shares rose about 1.5% to $273.18 at 10.55am ET time on Thursday morning.The trial found a 4.8-point greater reduction in mania symptoms than placebo…